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Short communication: Recombinant mammary serum amyloid A3 as a potential strategy 1 
to prevent intramammary infections in dairy cows at dry-off. By Parés et al. Dairy cows 2 
are most susceptible to incur intramammary infections during the dry period. Preventive 3 
strategies other than antibiotics may be extremely useful to decrease the infection risk without 4 
increasing antibiotic resistances. The use of recombinant mammary acute phase protein M-5 
SAA3 is a promising alternative because it is a key modulator of the mammary gland innate 6 
immunity. This study demonstrates the effects of M-SAA3 on mammary epithelia reducing the 7 
infections of four relevant mastitis pathogens in dairy cattle. 8 
 9 
Short communication: Recombinant mammary serum amyloid A3 10 
as a potential strategy to prevent intramammary infections in dairy 11 
cows at dry-off 12 
Sílvia Parés*, Francesc Fàbregas*, Àlex Bach*,†, Elena Garcia-Fruitós*, Ana de Prado‡ and 13 
Anna Arís*§  14 
 15 
*Department of Ruminant Production, IRTA (Institut de Recerca i Tecnologia 16 
Agroalimentàries), 08140 Caldes de Montbui, Spain 17 
†ICREA (Institució Catalana de Recerca i Estudis Avançats), 08010 Barcelona, Spain 18 
‡Corporate Ruminant Department. Ceva Sante Animale. Libourne, France 19 
§Corresponding author at: Department of Ruminant Production, IRTA (Institut de Recerca i 20 
Tecnologia Agroalimentàries), 08140 Caldes de Montbui, Spain. E-mail address: 21 




Mammary serum amyloid A3 (M-SAA3) has shown potential stimulating innate immunity 25 
during intramammary infections at calving and dry-off. Herein, we have produced recombinant 26 
caprine M-SAA3 to test its potential to reduce intramammary infections against 27 
Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, and Escherichia 28 
coli, which are common mastitis-producing pathogens. The recombinant production of M-29 
SAA3 followed by LPS-removal to avoid LPS-unspecific stimulation of the immune system 30 
was successfully achieved. Mammary serum amyloid A3 stimulated the expression of IL-8 in 31 
a dose-dependent manner in primary mammary cultures. Although a direct killing effect on S. 32 
aureus by M-SAA3 was not detected, the acute phase protein was able to reduce up to 50% S. 33 
aureus, S. uberis, and S. dysgalactiae infections and induced a reduction of 67% in E. coli 34 
counts. In general, the best concentration of caprine M-SAA3 at inhibiting infections was the 35 
lowest concentration tested (10 μg/ml), although greater concentrations of M-SAA3 (up to 160 36 
μg/ml) increased the antimicrobial potential against some pathogens. 37 
 38 
Key words: dry period, intra-mammary infections, immune response, M-SAA3 39 
 40 
Short Communication 41 
Mastitis is the inflammatory response of the mammary tissue to bacterial infections, and it 42 
represents one of the most economically costly diseases affecting dairy animals. The udder of 43 
the dairy cow is most susceptible to incur intra-mammary infections (IMI) during the dry 44 
period, which can persist throughout the next lactation, causing important economic losses 45 
(Oliver and Murinda, 2012) and discomfort to the animal (Bertulat et al., 2013). The reasons 46 
behind this prominent risk is that a relatively large volume of milk remains in the udder at dry-47 
off, which may lead to milk leakage (Tucker et al., 2009) and favor the colonization of the 48 
mammary gland by microorganisms (Schukken et al., 1993). Also, at dry-off, the immune 49 
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system is not fully active against pathogens because a reduced functional capability of 50 
mammary leukocyte population (Oliver and Sordillo, 1989) coupled with the fact that an 51 
important part of phagocytic cells arriving at mammary gland is engaged in removing fat and 52 
protein debris from the milk accumulated in the udder at dry-off (Burvenich et al., 2007). At 53 
present, the most common strategy to prevent IMIs at dry-off include: a) inducing a reduction 54 
of milk yield (through either reducing milking frequency (Tucker et al., 2009), nutrient supply 55 
(Ollier et al., 2014), or both, or the use of prolactin release inhibitors such cabergoline that also 56 
hasten mammary gland involution and enhance its immunity (Bach et al., 2015, Boutinaud et 57 
al., 2016, 2017)), 2) administering broad-spectrum antibiotics (Scherpenzeel et al., 2014), and 58 
3) applying teat sealants at drying (McParland et al., 2019). However, a concern exists that use 59 
of antibiotics could be associated with an increase in antibiotic-resistant bacteria, and some 60 
governments are implementing regulations to restrict the use of prophylactic intramammary 61 
antibiotics in non-infected cows at dry-off. However, Scherpenzeel et al. (2014) showed that 62 
quarters that did not receive antimicrobial treatment at dry-off had a 1.7 times greater incidence 63 
rate of clinical mastitis during the dry period and the first 100 d in the subsequent lactation, as 64 
compared with quarters  that did receive antibiotic treatment at dry-off.  65 
Mammary serum amyloid A3 (M-SAA3) is a naturally occurring acute phase protein produced 66 
locally and involved in the regulation of the local immunity and the regeneration of the 67 
mammary gland. The concentrations of M-SAA3 are greatest in colostrum, in milk during IMI, 68 
and at dry-off (Molenaar et al., 2009). A previous study (Domènech et al., 2014) has shown 69 
that intra-mammary infusion of recombinant M-SAA3 in the cow fostered the involution 70 
process, mainly through the activation of endogenous mammary matrix metalloproteinase -9 71 
(MMP-9) activity, which is involved in extracellular matrix remodeling. It has also been 72 
reported that M-SAA3 modulates the innate immunity by increasing mediators of the immune 73 
response, such as IL-8, to ultimately enhance neutrophil recruitment, maturation of dendritic 74 
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cells, and phagocytic activity by opsonization (Domènech et al., 2012, 2014). However, the 75 
role of recombinant M-SAA3 in the inhibition of infections caused by mastitic pathogens has 76 
not yet been studied in depth. Thus, the main objective of the present study was to explore the 77 
potential of M-SAA3 in the inhibition of the infection of primary bovine mammary epithelial 78 
cultures by common mastitis-producing pathogens including Escherichia coli, Streptococcus 79 
uberis, Staphylococcus aureus, and Streptococcus dysgalactiae. 80 
Herein, M-SAA3 was produced recombinantly without traces of endotoxins that could interfere 81 
with the immune function using either E. coli BL21 Star (DE3) or ClearColi® (Lucigen, 82 
Middleton, WI, USA) transformed with pET101/D-TOPO vector codifying for the His tagged-83 
goat M-SAA3 sequence isolated in a previous study (Domènech et al., 2012). Microbial cells 84 
were grown in 400 mL of LB-Amp media at an initial OD600 of 0.05 until log phase was 85 
achieved. Recombinant expression was induced by 0.1 mM IPTG at OD600 of 0.9-1 for 1 h and 86 
20 min in BL21 strain and at 0.6-0.7 for 2 h in ClearColi®. The cell pellet was obtained by 87 
centrifugation at 6,000 x g for 10 min, and frozen at -80°C until use, and then lysed in 36 mL 88 
Tris-buffered saline lysis buffer containing 1x Bugbuster® (Merck-Millipore, Billerica, MA, 89 
USA), 0.1% v/v benzonuclease (Sigma-Aldrich, Saint Louis, MO, USA), and 1x cOmplete® 90 
EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland). The lysed product was 91 
centrifuged for 15 min at 20,000 x g at 4 ºC. Supernatants containing protein were then used to 92 
obtain purified protein with the Amicon Pro System from Merck-Millipore (Billerica, MA, 93 
USA) and the Clontech (Mountain View, CA, USA) His60 agarose bead slurry (60 mg/mL 94 
binding capacity). Samples were eluted twice to ensure there was no protein left in the resin. 95 
The purified protein was dialyzed overnight at 4°C against PBS and quantified using 96 
spectrophotometry ((A280×Molecular weight)/Extinction coefficient; (mg/mL)). The removal 97 
of LPS from M-SAA3 produced in E. coli BL21 was carried out with the Mustang Q Acrodisc 98 
membrane (Pall Corporation, New York, USA) following manufacturer’s instructions. Briefly, 99 
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all samples and buffers were filtered through a 0.22 m filter before pushed through the 100 
membrane. The membrane was then washed with 5 mL 1 M NaOH and equilibrated with 1 mL 101 
1 M NaCl and 5 mL PBS before running the sample. The presence of possible endotoxin traces 102 
in purified M-SAA3 (LPS or Lipid IVA) was quantified by Microcoat Company using LAL 103 
Kinetic chromogenic assay. Protein production was assessed by SDS-PAGE in 12% 104 
polyacrylamide gels either with Coomassie or western blot as previously described (Gifre-105 
Renom et al., 2018). Samples were analyzed using a lineal method in an UltrafleXtreme 106 
MALDI-TOF instrument (Bruker Daltonics, Bremen, Germany) with ion acceleration of 25 107 
kV. In order to test M-SAA3 activity, mammary epithelial primary cultures were obtained from 108 
mammary tissue as described elsewhere (Domenech et al., 2014). Mammary epithelial cells 109 
were seeded in 24-well plates at 44,000 cells/well. After 24 h incubation at 37°C and 5% CO2, 110 
wells were washed twice with warm PBS to remove antibiotics, and treatments were applied 111 
in a final volume of 100 L of PBS + 400 L of medium (DMEM/F‐12 medium with 8 μg/mL 112 
bovine insulin and 50 μg/mL hydrocortisone) in the case of LPS and Lipid IVA or in 600 μL 113 
PBS + 400 μL of medium in the case of recombinant M-SAA3. After a 3 h incubation at 37°C, 114 
5% CO2, cells were gently washed with PBS, and 500 μL of Trizol reagent (Thermo Fisher 115 
Scientific, Madrid, Spain) were added to each well to collect and lysate the cells. Cell lysates 116 
were kept frozen at -80°C until RNA extraction. The extraction of RNA was performed using 117 
the TRizol reagent (Thermo Fisher Scientific, Madrid, Spain). Then, RNA was retrotranscribed 118 
to cDNA using the PrimeScript RT reagent kit (Takara Bio Inc, Shiga, Japan) following 119 
manufacturer’s instructions. The RNA purity was assessed using a Nanodrop 120 
instrument at 260, 280, and 230 nm, obtaining 260/280 and 260/230 ratios between 1.9-2.0 and 121 
2.0-2.2, respectively. Quantitative PCR was performed for genes encoding for IL-8 (Primer 122 
sequences: Fw: 5'-TTGAGAGTGGGCCACACTGTG-3', Rv: 5'-123 
TGCACCCACTTTTCCTTGG-3') and ACTB (Primer sequences: Fw: 5'-124 
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CTGGACTTCGAGCAGGAGAT-3', Rv: 5'-CCCGTCAGGAAGCTCGTAG-3') using a 125 
MyiQ Single Color Real-Time PCR Detection System Thermocycler (Bio-Rad, Madrid, Spain) 126 
with the SYBR Premix Ex Taq (Takara Bio Inc, Japan). Quantitative PCR conditions for each 127 
set of primers were individually optimized (ACTB: Annealing temperature = 57 ºC, primer 128 
concentration = 0.124 M; IL-8: Annealing temperature = 55 ºC, primer concentration = 0.5 129 
M). The specificity of the amplification was evaluated by the single band identification at the 130 
expected molecular weight in 0.8% DNA agarose gel, using each respective gene control, and 131 
a single peak in the qPCR melting curves. A standard curve of Ct versus log concentration was 132 
plotted to obtain the efficiency, which was calculated using the formula 10 -1/slope, with an 133 
acceptable range of 1.8-2.2 (Chow et al., 2010). Relative gene expression was calculated using 134 
the 2∆Ct method with ACTB as reference gene. 135 
Pathogenic E. coli, S. uberis, S. aureus, and S. dysgalactiae were isolated from mastitic milk 136 
kindly provided by ALLIC (Laboratori interprofessional lleter de Catalunya, Cabrils, Spain). 137 
All strains were grown in brain-heart infusion (BHI) media and plated onto Tripticasein Soy 138 
agar plates (S. dysgalactiae, S. uberis) or BHI agar plates (E. coli, S. aureus). Single colonies 139 
were grown in 10 mL of BHI media overnight at 37°C in static conditions. A cell pellet was 140 
obtained by centrifugation at 6,000 x g for 10 min at 4°C and kept frozen in 10% glycerol upon 141 
use. Before infection experiments, bacterial pellets were thawed at room temperature and 142 
grown overnight in 10 mL of BHI at 37 ºC in static conditions. Bacterial concentrations were 143 
determined by spectrophotometric quantifications according to previously established colony-144 
forming unit (CFU) counts (data not shown). Equivalence between OD600 and CFU/mL was 145 
the following: E. coli 5.00 = 5x109 CFU/mL, S. uberis 0.50 = 8.5x108 CFU/mL, S. aureus 5.00 146 
= 5.1x109 CFU/mL, and S. dysgalactiae 0.50 = 6.2x107 CFU/mL. Infective bacterial doses 147 
were obtained by resuspending and diluting the cell pellet in infection medium. Mammary 148 
epithelial cells were seeded in 24-well plates at a density of 44,000 cells/well in cell culture 149 
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medium (concentrations described above). After 24 h, cells were incubated with recombinant 150 
M-SAA3 (at a concentration of 10-160 g/ mL) for 1 h in a volume of 600 μL PBS + 400 μL 151 
infection medium. Negative control consisted of 600 μL PBS + 400 μL medium. After 1 h 152 
incubation at 37°C and 5% CO2 mammary cells were infected with 10
6 CFU/well and incubated 153 
in the same conditions for two more hours. Then, mammary cells were gently washed with 154 
0.5mL PBS twice and 0.5 mL of 0.9% NaCl was added until lysed. Mammary cell lysate 155 
obtained from each replicate was serially diluted and seeded in agar plates. Colonies were 156 
counted after 24-48 h of growth at 37°C. The experiment was repeated 3 times with 6 replicates 157 
per treatment. Also, direct bacterial killing activity of recombinant M-SAA3 was tested against 158 
S. aureus. A suspension containing 1x106 CFU was incubated with PBS with or without 160 159 
g/mL of recombinant M-SAA3 for 3.5 h and 5.5 h at 37°C. After incubation, viable bacteria 160 
were quantified by plating the suspension in agar plates. Data were transformed to achieve a 161 
normal distribution when necessary prior to statistical analyses. All data were analyzed using 162 
an analysis of variance that accounted for the effect of treatment (i.e., M-SAA3, LPS, or Lipid 163 
IVA).  164 
The M-SAA3 yields obtained after protein expression in E. coli BL21 and ClearColi® were 1.8 165 
and 1.33 mg/L culture with a purity of 98 and 95%, respectively. The two main bands of 15 166 
kDa and 10 kDa observed by Coomassie staining were identified as M-SAA3 by western blot 167 
using anti-His antibodies and MALDI-TOF analyses (data not shown). Also, a band 168 
corresponding to lysine decarboxylase CadA from E. coli was identified in M-SAA3 samples 169 
purified from ClearColi®. The inclusion of a second purification step based on a cation-170 
exchange chromatography for M-SAA3 obtained from ClearColi® allowed the removal of this 171 
contaminating protein. However, although the addition of this extra purification step increased 172 
the purity of M-SAA3, it also resulted in a loss of 70% of M-SAA3 yield (data not shown). 173 
The results indicated that the amount of Lipid IVA associated to 1 µg of M-SAA3 produced in 174 
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ClearColi® was much greater than the amount of LPS traces in 1 µg of M-SAA3 produced in 175 
BL21 strain (76 ng or 54 pmols of Lipid IVA compared with 0.08 ng or 0.016 pmols of LPS). 176 
Although it has been described that Lipid IVA does not trigger the TLR4-based responses in 177 
human cells (Planesse et al., 2015), an IL-8 stimulation when using high doses of Lipid IVA 178 
was observed herein. Since the amount of Lipid IVA traces was high in the purified M-SAA3 179 
protein, the use of high M-SAA3 concentrations (around 100 g) in bovine cell culture 180 
experiments and further in vivo assays would include a sufficient amount of Lipid IVA to 181 
stimulate IL-8 expression itself, which would interfere with the analysis of M-SAA3 activity. 182 
The inconsistent production rates and presence of high amounts of Lipid IVA in the 183 
recombinant product from Clearcoli were the main reason to select the protein produced in E. 184 
coli BL21 followed by a 800-fold LPS removal with Mustang filters. This final amount of LPS 185 
present should not interfere in the study of M-SAA3 functionality (< 0.001 EU (0.0001 ng 186 
LPS) /g of M-SAA3). 187 
The expression of IL-8 increased (P < 0.0001) up to 13-fold in M-SAA3 treatments compared 188 
with control in a dose-dependent manner, with 10 g/mL representing the lowest dose with a 189 
significant effect (Figure 1B). We were not able to demonstrate direct killing activity of S. 190 
aureus (Figure 3), which is one of the most important pathogens involved in IMI in dairy cows 191 
(Rainard, 2005). Molenaar et al. (2009) reported a moderate activity at 18 g/mL and a 192 
complete killing activity of E. coli at concentrations ≥63 g/mL of bovine M-SAA3.2. The 193 
greater effect on E. coli could be linked to a greater efficacy of M-SAA3 against Gram-negative 194 
microorganisms, due its binding affinity to OmpA (Hari-Dass et al., 2005; Molenaar et al., 195 
2009). Alternatively, differences observed between studies could be due to the sequence of the 196 
M-SAA3 protein used. Bovine and caprine M-SAA3 forms share the 91.3% of their nucleotide 197 
and 86.3% of their amino acid sequence, but they are not identical molecules. Moreover, the 198 
recombinant M-SAA3 produced herein lost a 9 amino acids at the N terminus of the native 199 
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mature form, which might be involved in this direct killing activity. However, MSAA-treated 200 
mammary epithelial cells had reduced bacterial counts of S aureus , S uberis and E coli with 201 
all the concentrations tested (Figure 2A, 2C, 2D). Specifically, a reduction of 50% of S. aureus 202 
infection was achieved at 160 g/mL. From a general point of view, the best concentration of 203 
caprine M-SAA3 at inhibiting infections was the lowest concentration tested (10 g/mL). In 204 
the case of S. dysgalactiae and E. coli (Figure 2A, 2B) this concentration elicited the best 205 
efficiency of inhibition, being 67 and 51%, respectively. In the case of S. aureus and S. uberis 206 
(Figure 2C, 2D), although 10 g/mL of SAA3 inhibited infection by 23 and 29%, respectively, 207 
greater concentrations of M-SAA3 (up to 160 g) increased the antimicrobial potential to 50%. 208 
Intriguingly, high M-SAA3 concentrations were not as efficient as low M-SAA3 209 
concentrations in E. coli and S. dysgalactiae. In contrast, the greatest concentrations of M-210 
SAA3 performed better with S. aureus and S. uberis than with E. coli. Regarding the direct 211 
bacterial killing of S. aureus, there was no effect of caprine M-SAA3 on the viability of S. 212 
aureus (Figure 3). Thus, it was decided to explore the potential effect of four different 213 
concentrations of M-SAA3 on the reduction of bacterial infection by S. aureus, S. dysgalactiae, 214 
S. uberis, and E. coli in mammary cultures. A decrease in bacterial infection with all four strains 215 
was found and, interestingly, the response to the different doses varied among the pathogens, 216 
which could be explained by the different inflammatory pathways elicited by different bacteria.  217 
It has been previously described that M-SAA3 binds to MD-2 to activate p38 and NF-κB 218 
pathways in a MyD88-dependent manner (Deguchi et al., 2013). This regulates not only the 219 
stimulation of inflammatory components such as several cytokines, but also the synthesis of 220 
antimicrobial peptides, tight junctions, and inflammation components that allow epithelial cells 221 
control the infection (Tak and Firestein, 2001; Zarubin and Han, 2005). Moreover, M-SAA3 222 
increases the expression of mucins in several tissues (Tashiro et al., 2017) and the mammary 223 
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gland expresses Mucin1 and Lingual Antimicrobial Peptide (LAP) as protective molecules 224 
(Isobe et al., 2009; Patton et al., 1995; Pallesen et al., 2001). 225 
As a Gram-negative bacterium, E. coli stimulates, the inflammatory response of epithelia via 226 
TLR4, which is also activated by M-SAA3. However, some authors have suggested that S. 227 
aureus does not activate this receptor at the same extent than in E. coli but mainly activates 228 
TLR2 instead (Fu et al., 2013). On the other hand, Yang et al. 2008 suggested that although S. 229 
aureus actives both TLR2 and TLR4, the pathogen impairs the final NF-kB activation (Yang 230 
et al., 2008). Thus, these observations suggest that there is a greater immune stimulation in E. 231 
coli than in S. aureus, which combined with M-SAA3 effects on the mammary cells could lead 232 
to an over-stimulation causing negative effects on the tissue (Blach-Olszewska et al., 2007). 233 
Alternatively, we could not discard a possible competitive effect for TLR4 between some 234 
bacteria strains used (E. coli / S. dysgalactiae) and M-SAA3. Although further research is 235 
needed to elucidate the exact mechanisms, it can be inferred that the recombinant M-SAA3 236 
used herein represents a plausible strategy to prevent IMI in dairy cows. 237 
Overall, these results show potential for the use of recombinant M-SAA3 in preventing 238 
IMI in dairy cows. We have demonstrated effects of recombinant M-SAA3 on mammary 239 
epithelia and bacteria resulting in the reduction of infection by four 240 
relevant mastitic pathogens, which coupled with the potential to recruit immune cells into the 241 
mammary gland, increased phagocytic activity and dendritic cells maturation (Domènech et 242 
al., 2014, 2012) make M-SAA3 a plausible alternative to antimicrobial agents to control IMI 243 
in cattle. 244 
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Figure 3. 371 












Figure captions 373 
Figure 1. A. Expression of IL-8 in primary mammary cell cultures treated with LPS (lined 374 
bars), Lipid IVA (dotted bars), or control (white bar) expressed in relative units (RU). Asterisks 375 
indicate differences from control. B. Expression of IL-8 in primary mammary cell cultures 376 
treated with different concentrations of recombinant M-SAA3 expressed as relative units (RU). 377 
Different letters denote differences (P < 0.05) among treatments. Error bars depict SEM at each 378 
time point. 379 
 380 
Figure 2. Bacterial counts or infective bacteria, expressed as CFU/mL, associated to mammary 381 
primary cell cultures after an infection with 106 CFU/mL of (A) S. dysgalactiae, (B) E. coli, 382 
(C) S. aureus, or (D) S. uberis and treated with different concentrations of recombinant M-383 
SAA3. Different letters denote differences (P < 0.05) among treatments. Error bars depict SEM 384 
at each time point. 385 
 386 
Figure 3. Bacterial counts expressed as CFU/mL of S. aureus treated with PBS in the absence 387 
(white bars) or presence (dashed bars) of 50 g/mL of recombinant M-SAA3. Error bars depict 388 
SEM at each time point. 389 
 390 
